Familial Hypercholesterolemia News and Research

RSS
Genzyme, Isis present mipomersen phase 3 study data in severe heFH at ACC meeting

Genzyme, Isis present mipomersen phase 3 study data in severe heFH at ACC meeting

Study sheds light on novel functions of certain PCSK enzymes

Study sheds light on novel functions of certain PCSK enzymes

Aegerion third quarter net loss increases to $6.2 million

Aegerion third quarter net loss increases to $6.2 million

Impax initiates challenge of patents relating to WELCHOL

Impax initiates challenge of patents relating to WELCHOL

VYTORIN reduces major vascular events in patients with chronic kidney disease

VYTORIN reduces major vascular events in patients with chronic kidney disease

Alnylam to present data on RNAi therapeutics for fibrotic diseases at The Liver Meeting

Alnylam to present data on RNAi therapeutics for fibrotic diseases at The Liver Meeting

Genzyme third quarter revenue increases to $1.0 billion

Genzyme third quarter revenue increases to $1.0 billion

Aegerion Pharmaceuticals’ MTP-I Phase III trial published in Atherosclerosis online supplement

Aegerion Pharmaceuticals’ MTP-I Phase III trial published in Atherosclerosis online supplement

USFDA grants Sun Pharma subsidiary tentative approval for generic Crestor ANDA

USFDA grants Sun Pharma subsidiary tentative approval for generic Crestor ANDA

Mipomersen Phase 3 trial in heFH meets primary, secondary and tertiary endpoints

Mipomersen Phase 3 trial in heFH meets primary, secondary and tertiary endpoints

Impax confirms initiation of challenge of patents listed by MSP Singapore for VYTORIN

Impax confirms initiation of challenge of patents listed by MSP Singapore for VYTORIN

Isis second-quarter pro forma net operating loss increases to $15.5 million

Isis second-quarter pro forma net operating loss increases to $15.5 million

Genzyme, Isis announce results of two mipomersen phase 3 studies

Genzyme, Isis announce results of two mipomersen phase 3 studies

Regeneron second-quarter total revenues increase to $115.9 million

Regeneron second-quarter total revenues increase to $115.9 million

Genzyme second-quarter revenue decreases to $1.08 billion

Genzyme second-quarter revenue decreases to $1.08 billion

Pfizer's new chewable Lipitor for children receives European Commission approval

Pfizer's new chewable Lipitor for children receives European Commission approval

GSK, Isis Pharmaceuticals collaborate to develop new therapeutics for rare and serious disease

GSK, Isis Pharmaceuticals collaborate to develop new therapeutics for rare and serious disease

Genzyme, Isis Pharmaceuticals: Phase 3 study of mipomersen in hoFH patients meets primary endpoint

Genzyme, Isis Pharmaceuticals: Phase 3 study of mipomersen in hoFH patients meets primary endpoint

Isis Pharmaceuticals reports revenues of $32.3M for fourth-quarter 2009

Isis Pharmaceuticals reports revenues of $32.3M for fourth-quarter 2009

Genzyme announces fourth-quarter and full-year 2009 financial results

Genzyme announces fourth-quarter and full-year 2009 financial results